Natera (NTRA)

• Market cap: $19.1B
• 1 day: -0.16%
• 5 days: -8.73%
• 1 month: -1.34%
• 3 months: -12.09%
• 6 months: 11.01%
• Year to date: -12.09%
• 1 year: 51.88%
• 5 years: 435.62%
• 10 years: 520.89%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Employees: 4,434

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

281% more first-time investments, than exits

New positions opened: 141 | Existing positions closed: 37

25% more capital invested

Capital invested by funds: $15.9B [Q3] → $19.8B (+$3.93B) [Q4]

21% more funds holding in top 10

Funds holding in top 10: 24 [Q3] → 29 (+5) [Q4]

19% more funds holding

Funds holding: 488 [Q3] → 582 (+94) [Q4]

0.77% more ownership

Funds ownership: 100.96% [Q3] → 101.73% (+0.77%) [Q4]

13% less repeat investments, than reductions

Existing positions increased: 181 | Existing positions reduced: 207

17% less call options, than puts

Call options by funds: $136M | Put options by funds: $163M

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $185 31% upside
• Avg. target: $202 43% upside
• High target: $251 78% upside

9 analyst ratings

• positive: 9 100%
• neutral: 0 0%
• negative: 0 0%

RBC Capital Conor McNamara 5% 1-year accuracy 2 / 37 met price target	78% upside $251	Outperform Initiated	13 Mar 2025
Morgan Stanley Tejas Savant 21% 1-year accuracy 4 / 19 met price target	31% upside $185	Overweight Maintained	5 Mar 2025
Piper Sandler David Westenberg 44% 1-year accuracy 19 / 43 met price target	45% upside $205	Overweight Maintained	4 Mar 2025
Canaccord Genuity Kyle Mikson 33% 1-year accuracy 9 / 27 met price target	38% upside $195	Buy Maintained	28 Feb 2025
Baird Catherine Ramsey 31% 1-year accuracy 5 / 16 met price target	33% upside $188	Outperform Maintained	28 Feb 2025